ABBV - AbbVie-partnered therapy selected for FDA's rare disease pilot program
2024-06-07 07:59:30 ET
More on AbbVie
- AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
- AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now
- Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
- AbbVie succeeds in mid-stage trial for ovarian cancer drug, Elahere
- AbbVie doses first patient in phase 3 trial of multiple myeloma asset